Claris Capital

The firm invites direct pitches from startups through its website and likely draws on the parent group's network across pharmaceuticals, healthcare, and clean energy. Founders can submit their businesses via the 'Pitch to Us' portal, bypassing traditional intermediary channels. This direct-sourcing model is designed to surface deals aligned with the parent's sector expertise.

Claris Capital is a wholly owned subsidiary of Claris Limited and invests off the corporate balance sheet. It does not operate as an independent fund with external limited partners. This structure gives the firm flexibility on holding periods and eliminates the need to raise successive fund vintages.

The firm primarily targets early-stage rounds from Seed through Series B. However, it also co-invests alongside other institutional investors in later-stage growth rounds ranging from Series C up to pre-IPO, depending on the opportunity.

Claris Capital has not published a formal exclusion list. Its stated focus areas — FinTech, Food-Tech, Healthcare, Logistics, Data Analysis, Fashion, and other consumer-centric businesses — suggest the firm is less likely to invest in heavy industrials, infrastructure, or deep-tech hardware, though no explicit prohibitions have been disclosed.

The capital is provided by Claris Limited, the parent group with over 20 years of operating history in pharmaceuticals, healthcare, education, clean energy, and agriculture. Claris Capital does not disclose targeted allocation amounts or the size of the balance-sheet facility it draws upon.

Claris Capital can both lead and co-invest. The firm states it 'typically engages with start-ups in early stage / pre-Series A to Series B' and is 'happy to co-invest with other investors in much later stage rounds.' This suggests the firm is comfortable as either a lead or a syndicate partner depending on the stage and round dynamics.

Claris Capital is a wholly owned subsidiary established to incubate and invest in new-age businesses, leveraging the parent group's operational experience. The investment team is expected to draw on Claris Limited's sector expertise in pharma and healthcare when underwriting deals, creating a strategic overlap between the venture portfolio and the parent's core industry knowledge.